Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TARA 
Protara Therapeutics Inc (TARA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: TARA (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $22.17
1 Year Target Price $22.17
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 201.1% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 117.67M USD | Price to earnings Ratio - | 1Y Target Price 22.17 |
Price to earnings Ratio - | 1Y Target Price 22.17 | ||
Volume (30-day avg) 7 | Beta 1.36 | 52 Weeks Range 1.59 - 6.88 | Updated Date 07/16/2025 |
52 Weeks Range 1.59 - 6.88 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.49 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.16% | Return on Equity (TTM) -41.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1782687 | Price to Sales(TTM) - |
Enterprise Value 1782687 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.74 | Shares Outstanding 38581900 | Shares Floating 34182373 |
Shares Outstanding 38581900 | Shares Floating 34182373 | ||
Percent Insiders 3.61 | Percent Institutions 76.24 |
Upturn AI SWOT
Protara Therapeutics Inc
Company Overview
History and Background
Protara Therapeutics Inc. is a clinical-stage company focused on developing transformative therapies for the treatment of cancer and rare diseases. Founded with the goal of addressing unmet medical needs, the company has focused on developing its pipeline through strategic acquisitions and internal development programs.
Core Business Areas
- TARA-002: An investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC).
Leadership and Structure
The company is led by a management team with experience in oncology and rare diseases. The organizational structure is typical for a biotech company, with departments focusing on R&D, clinical development, and commercial strategy.
Top Products and Market Share
Key Offerings
- TARA-002: Investigational cell therapy for NMIBC. It is currently in clinical trials. Market share data is not yet available as the product is not yet approved. Key competitors in the NMIBC space include Ferring Pharmaceuticals, Merck and Urogen Pharma.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with companies focused on developing novel therapies for various diseases. The oncology segment is particularly active.
Positioning
Protara is positioned as a clinical-stage company focused on developing therapies for cancer and rare diseases. Its competitive advantage lies in its investigational cell therapy TARA-002.
Total Addressable Market (TAM)
The TAM for NMIBC is significant and growing. Protara is positioned to capture a portion of this market if TARA-002 is approved. Market size is estimated to be over $1 Billion USD.
Upturn SWOT Analysis
Strengths
- Promising clinical-stage asset (TARA-002)
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Dependence on a single lead asset
- Limited financial resources compared to larger pharmaceutical companies
- Clinical trial risks and regulatory hurdles
Opportunities
- Successful clinical trial results leading to regulatory approval
- Expansion of pipeline through acquisitions or partnerships
- Potential for Orphan Drug designation and accelerated approval pathways
Threats
- Clinical trial failures
- Competition from other companies developing therapies for NMIBC
- Regulatory setbacks
- Funding challenges
Competitors and Market Share
Key Competitors
- MRK
- FGEN
- UROG
Competitive Landscape
Protara's success depends on demonstrating the efficacy and safety of TARA-002 compared to existing and emerging therapies for NMIBC.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by the advancement of TARA-002 through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of TARA-002. Analyst estimates will depend on clinical data.
Recent Initiatives: Recent initiatives include ongoing clinical trials for TARA-002 and exploration of potential partnerships.
Summary
Protara Therapeutics is a clinical-stage biotech company with potential in TARA-002 for NMIBC. Its success hinges on positive clinical trial outcomes and regulatory approval. Funding and competition are significant risks, while successful development presents considerable opportunity. Given the clinical stage, the company is speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protara Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2014-10-22 | Co-founder, CEO, President & Director Mr. Jesse Shefferman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.protaratx.com |
Full time employees 28 | Website https://www.protaratx.com | ||
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.